Kent, B; Milger-Kneidinger, K; Heaney, LG; Menzies-Gow, A; Shavit, A; Olinger, L; Jackson, DJ.
Baseline characteristics of patients with severe eosinophilic asthma treated with benralizumab who reduced to anti-inflammatory reliever only vs high-, medium- or low- dose inhaled corticosteroid/formoterol: SHAMAL post-hoc analysis
EUR RESPIR J. 2024; 64: PA5354
Doi: 10.1183/13993003.congress-2024.PA5354
Web of Science
FullText
FullText_MUG